Benjamin Han, a geriatrician and addiction medicine specialist at the University of California-San Diego, tells his students a cautionary tale about a 76-year-old patient who, like many older people, struggled with insomnia. “She had problems falling asleep, and she’d wake up in the middle of the night,” he said. “So her daughter brought her some…
This updated fact sheet provides the latest data on the global HIV/AIDS epidemic, including impact on affected and vulnerable populations, treatment and prevention efforts, and an overview of the U.S. and global responses to the epidemic.
Faced with potential federal spending cuts that threaten health coverage and falling childhood vaccination rates, Monica Soni, the chief medical officer of Covered California, has a lot on her plate — and on her mind. California’s Affordable Care Act health insurance exchange covers nearly 2 million residents and 89% of them receive federal subsidies that…
Over the past ten months, Pear Suite has partnered with seven health plans to recruit and onboard more than 1,000 community health workers
Since deploying the system, Gleason says, Prisma has seen improvements in team engagement, safety culture, and quality outcomes
In this episode, we’re joined by Emily Lindemer, an executive director at Morgan Health. Lindemer discusses a recent report she co-authored, which focuses on maternal health opportunities in employer-sponsored insurance. The post MedCity FemFwd: Comparing Maternal Health in Employer-Sponsored Populations vs. Medicaid appeared first on MedCity News.
Revolutions Medicines’ daraxonrasib met the main goals of its Phase 3 test in pancreatic cancer, posting results that were both statistically significant and clinically meaningful. The company now plans to file for speedy regulatory approval under a new FDA pilot program. The post Revolution Medicines Reports ‘Unprecedented’ Survival in Pivotal Pancreatic Cancer Trial appeared first…
Healthcare Economist was named the #4 health policy blog in 2025 by FeedSpot. My blog was also ranked as the #1 top health economics blog, the #4 public health blog, and #31 economics blog as well. I’m excited to receive this recognition!
The Alzheimer’s disease drugs that have reached the market in the past two years are antibodies designed to break up amyloid plaques. Vigil Neuroscience brings to Sanofi a different approach: an oral small molecule designed to activate microglia, immune cells that play a key role in brain health. The post Sanofi’s Neuro Pipeline Expands to…
Patients want to explore more holistic options and are becoming more educated and interested in their own health. However, this trend of growing trust in unchecked online health advice often introduces more risk to patients than help. The post Why GI Providers Should Care About That “Health Hack” appeared first on MedCity News.